Citi: Initiates 90-day catalyst observation period for INNOVENT BIO (01801) with a target price of HK$62.
Citibank expects that with the drive of new products, Sinda Bio's strong growth momentum will continue.
Citibank released a research report stating that they have started a 90-day catalyst observation period for INNOVENT BIO (01801). The bank expects that with the drive of new products, the strong growth momentum of INNOVENT BIO will continue. Taletrectinib (ROS1)/Mazdutide/IBI311 (IGF-1R)/IBI112 (IL-23 p19) are expected to be approved in the second half of this year or next year. The target price is 62 Hong Kong dollars, with a rating of "buy/high risk".
Related Articles
US Stock Market Move | Popular Chinese concept stocks rose broadly, with Alibaba Group Holding Limited Sponsored ADR (BABA.US) gaining more than 4%.
WEB3 META (08093) issues profit warning, expects annual loss attributable to shareholders of approximately HK$29 million to HK$31 million
CHINA ECOTOUR (01371) issues a positive profit alert, expecting annual profit attributable to shareholders of approximately HK$95 million to HK$105 million, turning from loss to profit year-on-year.
US Stock Market Move | Popular Chinese concept stocks rose broadly, with Alibaba Group Holding Limited Sponsored ADR (BABA.US) gaining more than 4%.
WEB3 META (08093) issues profit warning, expects annual loss attributable to shareholders of approximately HK$29 million to HK$31 million
CHINA ECOTOUR (01371) issues a positive profit alert, expecting annual profit attributable to shareholders of approximately HK$95 million to HK$105 million, turning from loss to profit year-on-year.
RECOMMEND
